Open AccessA Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Author(s) -
Peter C. Taylor,
Désirée van der Heijde,
Robert Landewé,
Shan McCue,
Sue Cheng,
Annelies Boonen
Publication year - 2021
Publication title -
the journal of rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.577
H-Index - 178
eISSN - 1499-2752
pISSN - 0315-162X
DOI - 10.3899/jrheum.201088
Subject(s) - apremilast , medicine , placebo , ankylosing spondylitis , adverse effect , tolerability , clinical endpoint , randomized controlled trial , gastroenterology , psoriatic arthritis , arthritis , alternative medicine , pathology
To evaluate the efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with active ankylosing spondylitis (AS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom